Pancreatic Cancer
Advertisement
Dr. Picozzi details PANOVA-3, where TTFields with chemo showed significant survival gains in advanced pancreatic cancer.
Bridging GI Oncology Care and Compassion: Dr. Joseph McCollom on Hope, Healing, and Human Connection
Dr. Joseph McCollom discusses his path to specialization in GI cancers and the pivotal role of palliative care in oncology.
Dr. Mahalingam shares preliminary results from the randomized phase 2 study of elraglusib with gemcitabine/nab-paclitaxel.
A post hoc analysis of the NAPOLI 3 trial offers insight into prolonged survival in mPDAC.
A therapy has shown a statistically significant OS benefit in patients with unresectable locally advanced pancreatic cancer.
Results of CASSANDRA may alter the standard of care for patients with resectable PDAC.
Dr. Reni breaks a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG for stage I-III PDAC.
The Claudin18.2 antibody-drug conjugate IBI343 is well tolerated and shows encouraging efficacy in patients with PDAC.
The phase 3 NEOPAN study has shown that FOLFIRINOX can significantly improve PFS compared with gemcitabine.
Researchers evaluated the use of mFOLFIRINOX for the treatment of patients with resectable pancreatic adenocarcinoma.
Dr. El-Rayes reflects on his career in translational research, emphasizing his efforts to expand trial infrastructure.
Dr. Cleary discusses DDR deficiencies in metastatic pancreatic cancer and reviews the use of PARP inhibitors.
Zenocutuzumab may serve as an effective treatment for NRG1 fusion-positive pancreatic cancer, with low-grade AEs.
Drs. Stephen Liu and Benjamin Weinberg continue their discussion on the safety of zenocutuzumab in NRG1 fusion+ PDAC.
Drs. Stephen Liu and Benjamin Weinberg elaborate on the prevalence of NRG1 gene fusions in PDAC.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Challenges in designing and conducting clinical trials for patients with metastatic pancreatic ductal cancer are discussed.
The efficacy and safety of MEK inhibitors are compared to chemotherapy and other targeted therapies.
The KRAS G12R mutation is analyzed against other alterations in pancreatic adenocarcinoma, and research findings are shared.
Dr. Strosberg focuses on how previous exposure to alkylating agents can influence tumor biology or immune response.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.